Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in Human, Phase 1 Safety Study in Two Parts to Determine the Safety, Tolerability and Anti-cancer Immune-modulatory Effects of MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal of the Tumour

Next Previous
Search
Trial Profile

A First in Human, Phase 1 Safety Study in Two Parts to Determine the Safety, Tolerability and Anti-cancer Immune-modulatory Effects of MRx0518 in Patients With Solid Tumour Awaiting Surgical Removal of the Tumour

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CJRB 102 (Primary)
  • Indications Bladder cancer; Breast cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Urethral cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Acronyms MICROBIOME

    • Most Recent Events

    • 06 Jun 2023 Results reporting long-term subject follow-up, and further signals of immune modulatory changes from flow cytometry analysis presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 10 Aug 2022 Planned End Date changed from 1 Feb 2022 to 31 Dec 2022.
    • 10 Aug 2022 Planned primary completion date changed from 1 Aug 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top